Trial Profile

A Phase 1 open label study to determine safety, tolerability, and pharmacokinetics of SB206 for treatment of molluscum

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Berdazimer sodium (Primary)
Indications Molluscum contagiosum
Focus Adverse reactions
Acronyms B-SIMPLE3
Sponsors Novan Inc

Most Recent Events

10 Jan 2024 Acoording to the Results presented in Novan -Sec-2020, final study report was completed in the third quarter of 2020.
10 Jan 2024 Acoording to the Results presented in Novan -Sec-2020, 31 (91%) patients completed the pharmacokinetic assessment phase, and 29 patients (85%) went on to continue study participation for the full 12 weeks of treatment.
10 Jan 2024 Acoording to the Results presented in Novan -Sec-2020, enrollment was completed in the fourth quarter and all patients completed visits for B-SIMPLE3 in the first quarter of 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com